Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluorouracil
Drug ID BADD_D00931
Description A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Indications and Usage For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
Marketing Status approved
ATC Code L01BC02
DrugBank ID DB00544
KEGG ID D00584; D07974
MeSH ID D005472
PubChem ID 3385
TTD Drug ID D05LEO
NDC Product Code 62049-185; 16110-812; 16729-276; 68001-266; 16714-178; 25021-215; 51672-4063; 63323-117; 68083-293; 70700-187; 51927-1085; 62332-751; 38779-3185; 0378-8078; 68071-2961; 68083-270; 70700-188; 28105-421; 0378-4791; 68001-524; 68001-525; 68083-269; 12070-0002; 38779-0025; 59348-0055; 16729-542; 46708-751; 51672-4118; 70700-186; 70700-189; 51862-362; 68083-292; 49452-3175; 0187-5200; 51672-4062; 62991-1486; 0187-3204
UNII U3P01618RT
Synonyms Fluorouracil | 5FU | 5-FU | 5-Fluorouracil | 5 Fluorouracil | Fluoruracil | 5-FU Lederle | 5 FU Lederle | 5-FU Medac | 5 FU Medac | 5-HU Hexal | 5 HU Hexal | Adrucil | Carac | Efudix | Fluoro-Uracile ICN | Fluoro Uracile ICN | Efudex | Fluoroplex | Flurodex | Fluorouracil Mononitrate | Fluorouracil Monopotassium Salt | Fluorouracil Monosodium Salt | Fluorouracil Potassium Salt | Fluorouracil-GRY | Fluorouracil GRY | Fluorouracile Dakota | Dakota, Fluorouracile | Fluorouracilo Ferrer Far | Fluracedyl | Haemato-FU | Haemato FU | Neofluor | Onkofluor | Ribofluor | 5-Fluorouracil-Biosyn | 5 Fluorouracil Biosyn
Chemical Information
Molecular Formula C4H3FN2O2
CAS Registry Number 51-21-8
SMILES C1=C(C(=O)NC(=O)N1)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.001103%
Abdominal pain07.01.05.0020.002206%
Abdominal tenderness07.01.05.0040.000276%Not Available
Abortion spontaneous18.01.04.001--Not Available
Acute hepatic failure09.01.03.0010.000276%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.001562%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.002206%Not Available
Acute promyelocytic leukaemia16.01.05.003; 01.10.05.0030.000276%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.004--Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000827%
Acute respiratory failure22.02.06.001; 14.01.04.0040.000551%Not Available
Adenocarcinoma16.16.01.0040.000184%Not Available
Agranulocytosis01.02.03.0010.001287%Not Available
Alopecia23.02.02.0010.002518%
Altered state of consciousness19.07.01.003; 17.02.04.0010.000551%Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.0010.005699%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000551%Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.0070.000368%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.001287%
Angina unstable24.04.04.004; 02.02.02.0040.000184%Not Available
Aortic thrombosis24.01.09.0010.000276%Not Available
Aphasia17.02.03.001; 19.21.01.0010.000368%
Aphthous ulcer07.05.06.0020.000368%Not Available
Aplastic anaemia01.03.03.0020.000184%Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.003309%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.001875%Not Available
Application site pain12.07.01.004; 08.02.01.0040.003621%Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.0050.000625%Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 18 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene